

Proper management approach toward essential thrombocythemia

Authors:

Alshahrani Mohammed Saeed, Abdulaziz Abdullah Ali Alqahtani, Mazen Ali Saad Alqahtani, Ahmed Mousa Khalawi Mawkili, Abdullah Ibrahim Ali Asiri, Mohammed Raiy Ahmed Asiri, Abdullah Saeed Abdullah Al-bishi, Alaa Ahmed Almasabi

Abstract: In this article, we discuss pathophysiology, outline the diagnostic approach and treatment of essential thrombocythemia, as well as risk factors. Medline, and Embase, databases were searched for relevant studies discussing the essential thrombocythemia through, October, 2017. Platelet level is increased in essential thrombocythemia and it is very important to underscore the prognostic relevance of distinguishing from early/prefibrotic myelofibrosis and to raise awareness of relatively high risk of residual thrombosis in certain patients with defined ET. As the treatment low-dose aspirin combined with hydroxyurea may represent a satisfactory treatment of patients over the age of 60 years, but there is a need of disease-modifying drugs for younger patients. However, a definitive treatment of ET remains dependent on exclusion of the numerous reactive, hereditary, and neoplastic causes of thrombocytosis.

 **Introduction:**

Essential thrombocythemia (ET) is an obtained Myeloproliferative disorder (MPD) defined by a continual altitude of the platelet number with a propensity to thrombosis and also hemorrhage. Raised platelet matter is connected to a growth of megakaryocytic family tree and also the condition is normally thought about to be a clonal condition emerging in a multipotent stem cell. Essential thrombocythemia (ET), polycythemia vera (PV) and also primary myelofibrosis (PMF) are operationally categorized as BCR-ABL1-negative myeloproliferative neoplasms (MPN) [1]. All 3 are thought to stem from a genetically changed stem cell, which brings about clonal myeloproliferation. Neither the disease-initiating neither leukemia-promoting occasions in BCR-ABL1-negative MPN are understood, although most of the patients nurture JAK2V617F or various other second somatic mutations [2]. In regards to medical diagnosis, the World Health Organization (WHO) category system for hematopoietic tumors takes into consideration clonal erythrocytosis as specifying to PV, and also utilizes bone marrow morphology to compare ET and PMF [3]. The occurrence in the basic populace is around 30/100,000. The typical age at

medical diagnosis is 65 to 70 years, yet the condition might happen at any type of age. The women to male proportion refers 2:1. The scientific photo is controlled by a tendency to vascular occlusive occasions (including the cerebrovascular, coronary as well as peripheral circulation) and hemorrhages. Some patients with ET are asymptomatic, others might experience vasomotor (headaches, aesthetic disruptions, faintness, irregular chest discomfort, distal paresthesias, erythromelalgia), thrombotic, or hemorrhagic disruptions. Arterial and venous thromboses, in addition to platelet-mediated short-term occlusions of the microcirculation as well as bleeding, stand for the primary threats for ET patients. Thromboses of big arteries stand for a significant reason for death related to ET or could generate serious neurological, cardiac or outer artery symptoms. Acute leukemia or myelodysplasia stand for just unusual as well as often later-onset occasions. The molecular pathogenesis of ET, which brings about the overproduction of developed blood cells, resembles that located in various other clonal MPDs such as chronic myeloid leukemia, polycythemia vera and also myelofibrosis with myeloid metaplasia of the spleen.

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. In this article, we discuss pathophysiology, outline the diagnostic approach and treatment of essential thrombocythemia, as well as risk factors.

Methodology:

Medline, and Embase, databases were searched for relevant studies discussing the essential thrombocythemia through, October, 2017. Search restriction was applied to only English

language published studies with human subjects, further we scanned the references of included studies for more concerned articles.

Discussion:

- **Pathophysiology**

Essential thrombocythemia (ET) comes from a family members of relevant conditions identified by an uncontrollable cell development, called myeloproliferative neoplasms (MPNs), likewise consisting of polycythemia vera (PV) and primary myelofibrosis (PMF). Worldwide Health Organization (WHO) category, words 'tumor' was presented as opposed to 'problem' in order to underscore the clonal personality of the illness. ET without a doubt has the most effective diagnosis of the 3, with anticipated life period near typical [4].

The phenotypes of the 3 associated neoplasms vary significantly, even if there are resemblances. In PV, the primary attribute is raised red cell mass as well as in ET raised platelet degrees, whereas anemia is the highlight in myelofibrosis (MF). Thrombocytosis is a requirement for the medical diagnosis of ET, however, might go along with both of the others, although even more rarely. Shifts might happen: ET might become PV or MF, as well as PV might turn into MF. One school of thought counts on a pathophysiological continuum, beginning with ET and also finishing in MF. Nevertheless, this advancement is seen in a little minority of patients. Rather a lot more usual is the shift from ET straight to MF, yet also this is an unusual occasion, making it not likely that the continuum theory might describe the standard pathophysiology.

That made the continuum theory appealing was the discovery of the V617F mutation in the tyrosine pseudokinase area of the JAK2 genetics, being a gain-of-function mutation, leading to uncontrollable mobile development in the hematopoietic area. It is discovered in > 95% of PV patients, however just in 50-60% of ET and also MF patients. Consequently, it is still an open question which function the anomaly has for the advancement of illness in ET and also MF. The visibility of a JAK2V617F mutation suggests MPNs, yet does not distinguish in between them. The allele concern of the altered JAK2 genetics is a lot reduced in ET compared to in PV, and also homozygous altered cells are rarely discovered in ET yet prevail in PV.

- **Clinical description**

The medical discussion of ET is controlled by a proneness to vascular occlusive occasions as well as hemorrhages..

Vascular occlusive events

Vascular occlusive occasions consist of significant thrombotic occasions entailing the cerebrovascular, coronary and also peripheral arterial circulation. Thromboses of big arteries stand for a significant reason for death connected with the illness or could generate serious neurological, cardiac or outer arteries impairments.

Deep vein thrombosis likewise stands for a possibly major and also ultimately dangerous occasion because of the threat of lung embolism or pertaining to the area included as it holds true in hepatic (Budd Chiari syndrome) or portal thrombosis [5].

Vascular occlusive occasions could likewise happen in the micro-vessels where they trigger a vast array of medical signs and symptoms, second to a temporal suspension of the circulation.

They are brought on by platelet-mediated short-term occlusive thrombosis in the end-arterial flow [6]. Aspirin-sensitive erythromelalgia, among one of the most particular microvascular disruptions in ET, is referred to as burning very painful and ulcerative toes. It is commonly accompanied by a cozy, red or violet tinted stuffed arm or leg extremity. The ischemic assaults of electronic arteries might consequently proceed to little areas of restricted necrosis or perhaps outer gangrene with apparent arterial pulsations.

Headaches are one of the most usual neurological indications. Their pathophysiology stays unclear. A few of them look like migraine headaches. Often, neurological symptoms in ET reveal a striking resemblance with migraine mood or enhancements. On the other hand, short-term normal or irregular ischemic assaults, convulsions and also unexpected transitory lacks appear to arise from an ischemic device. Aesthetic disorder materializes as strikes of diplopia as well as unexpected relatively easy to fix strikes of obscured vision. All these symptoms share a details reversibility or a minimum of level of sensitivity to anti-aggregating agents and also happen, at the very least in more youthful ET patients, in the lack of noticeable atheromatous sores in the arterial system.

Hemorrhagic manifestations

Hemorrhaging in ET is usually restricted to persistent skin symptoms: wounding, subcutaneous hematomas, ecchymoses, as well as epistaxis or gum tissue bleeding. Petechiae are never ever seen. A background of intestinal blood loss (melena and/or hematemesis) or organic proof for chronic occult blood loss could be provened at medical diagnosis. Second bleeding, at some point dangerous could additionally happen after injury or surgical procedure. Hemorrhagic problems are seldom observed throughout the program of the condition when suitable safety nets are taken.

Bleeding signs and symptoms are largely observed in patients with the greatest platelet counts [7].

Asymptomatic presentation

The regularity of thrombohemorrhagic difficulties at the discussion of ET differs extensively in the various retrospective research studies. In a group of 809 ET patients detected in accordance with the Polycythemia Vera Study Group (PVSG) standards from 11 retrospective professional researches [8], the occurrence of thromboembolic occasions without blood loss was 42%, bleeding signs without thrombosis took place in 1.4%, as well as both bleeding and also thrombosis in 15% of the patients. The arterial thrombotic indications were called microcirculatory disruptions in 41%. Nonetheless, one of the essential messages of this retrospective collection was that 36% of ET patients were devoid of signs at medical diagnosis [9]. It is likewise essential to keep in mind that a number of them continued to be devoid of problems throughout the development of ET.

- **Diagnosis**

Because of the absence of a particular molecular marker, the medical diagnosis of ET could just be resolved after a detailed removal of the various other professional circumstances connected with a lengthy altitude of the platelet number. The standards of this step-by-step removal were originally recommended by the PVSG [10]. A lot more lately, the World Health Organisation (WHO) has actually recommended an enhanced brand-new collection of requirements where certain irregularities of megacaryocytopoiesis related to various other bone marrow biopsy searchings for were recommended as an usual favorable marker of Ph-negative MPDs [11]. The JAK2 V617F anomaly plainly stands for a brand-new molecular pen for the Ph-negative patients.

Originally defined in PV patients, where it has actually been observed in 65% to 97% of the situations [12], this mutation has actually additionally been spotted in parts of each of the various other Ph-negative MPDs: in 23 to 57% of ET and also 43 to 67% of IMF patients, along with in some Ph-negative CML and also MDS [13]. The visibility or lack of the V617F mutation does not purely associate with any type of phenotype of Ph-negative MPD identified in accordance with either the PVSG requirements or the WHO category. As the lack of the mutation has actually been repetitively verified in greater than 50% of ET patients, the medical diagnosis of ET currently continues to be a combination of: 1) favorable non particular disagreements for a Ph-negative MPD, consisting of the JAK2 anomaly and also the bone marrow (BM) biopsy searchings for and also 2) removal of PV as well as IMF in accordance with their presently utilized as well as phenotypically based meanings [10].

Arguments supporting the diagnosis of Ph-negative MPD

- Standard histological BM functions have actually been presented in the WHO analysis requirements for Ph-negative MPDs. The analysis target of histopathology in patients providing a raised platelet matter in accordance with this category might be twofold:

- 1) To verify the visibility of a Ph-negative MPD and also omit long-term responsive thrombocytoses (Rth). This action can be accomplished with a methodical evaluation of: a) megacaryocytopoiesis, concentrating particularly on the percentage of gigantic vs. tiny kinds, nuclear lobulation, growth flaws, collection development by megacaryocytes; b) BM cellularity; c) level of growth and of left moving of granulocyte and also erythrocyte family trees; d) densification of the reticulin network and existence of collagen fibrosis in the BM stroma [14].

2) To provide a details morphologic summary of each of the Ph-negative MPDs. For example in ET, megakaryocytopoiesis is defined by the existence of huge to gigantic cells with a control of hyperlobulated staghorn cores freely gathered throughout the BM. Cellularity in ET is not considerably raised compared to age-matched typical examples, as well as neutrophil granulopoiesis and also erythropoiesis show no substantial modification in the circulation and also expansion of both cell family trees. In real ET there is no collagen fibrosis and also no boost in reticulin fibers of the myeloid stroma [15].

- **Elimination of the causes of secondary thrombocytoses**

The primary reasons for additional thrombocytoses consisting of: iron deficiency, malignancy, chronic inflammatory condition, or backgrounds of splenectomy or of lengthy marrow regrowth need to be left out.

Removal of iron shortage consists of a regular or raised serum ferritin degree in the lack of inflammatory indices (erythrocyte sedimentation rate, fibrinogen, C-reactive protein (CRP)) as well as regular red cell mean corpuscular quantity. This action continues to be a crucial one in the medical diagnosis of ET, both to omit thrombocytoses connected to body iron supply deficiency and also to acknowledge PV covered up by iron shortage.

- **Risk categories of patients with ET**

A lot of the published therapy algorithms [16] rely upon the principle of a danger stratified management. Most of them identified 3 threat classifications based generally on the evaluation of the thrombohemorrhagic threat. This restricted aspiration results from that presently there is no medicine understood to treat the underlying illness or to avoid the danger of clonal development.

The present reasoning for utilizing medications is consequently either to stop, or even more hardly ever, to deal with a thrombohemorrhagic occasion.

High risk patients

The requirements acknowledged as significant threat of thrombosis and also embolism by mostly all private investigators [17] are:

- Age: the danger raises substantially in patients older compared to 60 years.
- Previous thrombotic occasion.

When the stratification additionally consists of an examination of the danger of significant hemorrhage [16], one of the most often thought about elements are:

- Platelet count $>1500 \times 10^9/L$.
- History of major bleeding or, as learned from The European Collaboration on Low-dose aspirin in Polycythemia Vera (ECLAP) experience, a history of minor bleeding with a platelet count $>1000 \times 10^9/L$, especially in patients with a long disease duration >15 years) [18].

Low risk patients

One of the most limiting meaning of patients at low risk consists of:

- Patients aged less than 40 years.
- Patients providing without high danger function.
- Patient without cardiovascular danger aspect and also thrombophilia of scientifically substantial family expression

Intermediate risk patient

Intermediate danger patients stand for a classification without a clear agreement on its interpretation. The threat of thrombosis is commonly considered intermediate in accordance with:

- Age (patients aged in between 40 and 60 years).
- Well developed danger variables of heart disease (high blood pressure, diabetes, cigarette smoking and also hypercholesterolemia). In the Medical Research Council (MRC) PT1 research the visibility of these elements was also enough to consist of patients in the high threat team.
- An intermediate risk pertaining to a platelet matter in between 1000 and also $1500 \times 10^9/L$ has likewise been suggested [18]. In this instance, the platelet number was considered enhancing the thrombotic risk when connected with a vascular threat aspect or family thrombophilia [16], as well as the hemorrhagic danger when linked to either small blood loss or long-term period of the illness [18].

- **Therapeutic intervention in ET patients**

To decrease the vascular danger in ET patients (besides the management of relatively easy to fix cardio danger variables) the restorative treatment is restricted to the choice of reducing the platelet matter or modifying the platelet function by aspirin or an equal treatment.

A. Anti-platelet treatment

Aspirin (and alternative anti-platelet agents)

Aspirin (Asp) is the conventional treatment for ischemic symptoms of the microcirculation. Decreasing the variety of platelets additionally undermines the signs. Continual Asp treatment is shown when the occlusive symptoms of the microcirculation continue regardless of decreasing the variety of platelets.

The duty of Asp in the avoidance of arterial thromboses has actually been plainly developed in the basic populace. The advantage of a reduced dosage Asp in preventing the threat of thrombotic issues without enhancing dramatically the hemorrhagic threat in PV patients has actually just recently been shown in the comprehensive potential ECLAP research [19]. An initial pilot research study in polycythemia patients getting either 40 mg/day of Asp or a sugar pill revealed that this dose completely prevented the cyclooxygenase task and also did not trigger any type of significant hemorrhage [20]. Anti-platelet treatment has not yet prospectively been revealed to minimize the occurrence of thrombosis in ET, nevertheless, the mix of an anti-aggregating agent with cytoreductive treatment has actually been located to be secure as well as to minimize the occurrence of thrombosis in ET patients in retrospective research studies [21].

B. Platelet-lowering treatment

Hydroxyurea (HU) has actually become the recommendation platelet-lowering agent in high threat ET patients. A beneficial platelet reducing in addition to anti thrombotic task has actually been shown in both of the (just) 2 released randomized potential tests worrying the therapy of this classification of patients [22]. Nevertheless, the still recurring conflict (inuing accordance with whether HU is leukemogenic) has actually motivated the factor to consider of 2 major different medicines: anagrelide, currently licensed for advertising and marketing in European nations, and also interferon α (IFN- α). 2 additional medicines, pipobroman (available just in particular European nations) and also busulfan are likewise taken as platelet-lowering medicines in ET patients, along with platelet apheresis, which might be the favored healing choice in case of emergency situation.

C. Alternative cytoreductive therapy

Pipobroman (PI)

Pipobroman (PI) is a piperazine by-product. PI shows up to competitively hinder pyrimidines though it reveals an architectural similarity to alkylating representatives.

Efficiency

The effectiveness of PI in controlling the platelet amount in patients with ET is near to that of HU, with a total reaction around 95%, recorded in numerous accomplice research studies [23]. In 118 ET patients at high threat for thrombosis dealt with by PI, drawn-out hematological remissions and also excellent professional and also hematological resistances have actually been reported after a lengthy follow-up [24].The advancing threat of thrombosis at year 10 amounted to 14%. Consequently, although not shown by potential or relative research studies, PI has most likely, like HU, a function in stopping thrombotic occasions in high danger patients.




Figure 1.Contemporary treatment algorithm in essential thrombocythemia. CVR, cardiovascular risk factors[25].

Conclusion:

Platelet level is increased in essential thrombocythemia and it is very important to underscore the prognostic relevance of distinguishing from early/prefibrotic myelofibrosis and to raise awareness of relatively high risk of residual thrombosis in certain patients with defined ET. As the treatment low-dose aspirin combined with hydroxyurea may represent a satisfactory treatment of patients over the age of 60 years, but there is a need of disease-modifying drugs for younger patients. However a definitive treatment of ET remains dependent on exclusion of the numerous reactive, hereditary, and neoplastic causes of thrombocytosis.

Reference:

1. Touati G, Poggi-Travert F, Ogier de Baulny H. Long-term treatment of persistent hyperinsulinaemic hypoglycemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. *Eur J Pediatr.* 1998;157(8):628–633. et al.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia* 2010; 24: 1128–1138.
3. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. *Leukemia* 2013;
4. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. *Semin Thromb Hemost.* 2006;32:171–173.
5. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Brière JB. Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic thrombosis.
6. Michiels JJ, Berneman Z, Bockstaele DV, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. *Semin Thromb Hemost.* 2006;32:174–207.
7. Van Genderen PJJ, Budde U, Michiels JJ, van Strik R, van Vliet HHMD. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. *Br J Haematol.* 1996;93:362–965. doi: 10.1046/j.1365-2141.1996.d01-1729.x.
8. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. *Semin Thromb Hemost.* 1997;23:371–377.
9. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. *Leuk Lymphoma.* 1996;22:149–160.
10. Murphy S, Peterson P, Illand H, Lazlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. *Semin Hematol.* 1997;34:29–39.
11. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editor. *World Health Organization Classification of Tumours Pathology and genetics of tumours of haematopoietic and lymphoid tissues.* Lyon, IARC press; 2001. pp. 39–41.
12. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N,

- Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia Vera. *Nature*. 2005;434:1444–1148. doi: 10.1038/nature03546.
13. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. *Blood*. 2005;106:3370–3373.
 14. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. *Leuk Lymphoma*. 1996;22:15–29.
 15. Thiele J, Kvasnika HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. *Semin Thromb Hemost*. 2006;32:219–230. doi: 10.1055/s-2006-939433.
 16. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. *Haematologica*. 2004;89:215–232.
 17. Harrison C. Essential thrombocythaemia: challenges and evidence-based management. *Br J Haematol*. 2005;130:153–165.
 18. Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for futures studies. *Semin Thromb Hemost*.
 19. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med*. 2004;350:114–124. doi: 10.1056/NEJMoa035572.
 20. Low dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia. *Br J Haematol*. 1997;97:453–456.
 21. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. *Clin Appl Thromb Hemost*. 1999;5:131–135.
 22. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med*. 1995;332:1132–1136.
 23. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, Volpe G, Pistorio A, Giardini I, Rocca B, Caresana M, Lazzarino M, Bernasconi C. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. *Leukemia*. 2002;16:2078–2083.

24. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, Pascutto C, Cazzola M, Lazzarino M. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. *Ann Hematol.* 2004;83:495–497.
25. Tefferi A, Barbui T. Personalized management of essential thrombocythemia—application of recent evidence to clinical practice. *Leukemia.* 2013;27(8):1617-1620. doi:10.1038/leu.2013.99.

IJSER